Rational development of a HIV-1 gene therapy vector

被引:28
作者
Anson, DS
Fuller, M
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Adelaide, SA 5006, Australia
[2] Univ Adelaide, Dept Paediat, Adelaide, SA 5005, Australia
关键词
HIV; gene therapy; vector; optimisation;
D O I
10.1002/jgm.415
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background HIV-1 provides an attractive option as the basis for gene transfer vectors due to its ability to stably transduce non-cycling cell populations. in order to fully utilise the promise of HIV-1 as a vector it is important that the effects of viral cis sequence elements on vector function are carefully delineated. Methods In this study we have systematically evaluated the effect of various cis elements from the HIV-1 YU-2 genome that have been implicated as either affecting vector performance, or HIV-1 replication, on the efficiency of vector production (titre and infectivity). As a measure of the relative safety of vectors their propensity to inadvertently transfer the gagpol gene to transduced cells was assessed. Results Sequences that were found to increase vector titre were from the 5' end of the gag gene, from the 5' and 3' ends of the env gene, from immediately upstream of the polypurine tract, and the central polypurine tract. The substitution of the HIV-1 RRE with heterologous RNA transport elements, or the deletion of the RRE, resulted in greatly reduced vector titres. RNA analysis suggested that the role of the Rev/RRE system extends beyond simply acting as an RNA nuclear export signal. The relative safety of different vector designs was compared and an optimal construct selected. Conclusions Based on our results we have constructed a vector that is both more efficient, and has better safety characteristics, than the widely used pHR' HIV-1 vector construct. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:829 / 838
页数:10
相关论文
共 37 条
[1]  
Blomer U, 1997, J VIROL, V71, P6641
[2]   A SMALL ELEMENT FROM THE MASON-PFIZER MONKEY VIRUS GENOME MAKES HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 EXPRESSION AND REPLICATION REV-INDEPENDENT [J].
BRAY, M ;
PRASAD, S ;
DUBAY, JW ;
HUNTER, E ;
JEANG, KT ;
REKOSH, D ;
HAMMARSKJOLD, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1256-1260
[3]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728
[4]   A 2ND ORIGIN OF DNA PLUS-STRAND SYNTHESIS IS REQUIRED FOR OPTIMAL HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION [J].
CHARNEAU, P ;
ALIZON, M ;
CLAVEL, F .
JOURNAL OF VIROLOGY, 1992, 66 (05) :2814-2820
[5]   Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function [J].
Cui, Y ;
Iwakuma, T ;
Chang, LJ .
JOURNAL OF VIROLOGY, 1999, 73 (07) :6171-6176
[6]   Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element [J].
Donello, JE ;
Loeb, JE ;
Hope, TJ .
JOURNAL OF VIROLOGY, 1998, 72 (06) :5085-5092
[7]   A third-generation lentivirus vector with a conditional packaging system [J].
Dull, T ;
Zufferey, R ;
Kelly, M ;
Mandel, RJ ;
Nguyen, M ;
Trono, D ;
Naldini, L .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8463-8471
[8]   Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors [J].
Follenzi, A ;
Sabatino, G ;
Lombardo, A ;
Boccaccio, C ;
Naldini, L .
HUMAN GENE THERAPY, 2002, 13 (02) :243-260
[9]   Helper plasmids for production of HIV-1-derived vectors [J].
Fuller, M ;
Anson, DS .
HUMAN GENE THERAPY, 2001, 12 (17) :2081-2093
[10]   Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors [J].
Gasmi, M ;
Glynn, J ;
Jin, MJ ;
Jolly, DJ ;
Yee, JK ;
Chen, ST .
JOURNAL OF VIROLOGY, 1999, 73 (03) :1828-1834